-
Mashup Score: 0
Niels W.C.J. van de Donk, MD, PhD, presents 2-year follow-up results from the MajesTEC-1 trial, which indicated that teclistamab demonstrated safety and efficacy among heavily pre-treated patients with R/R multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Teclistamab Plus Talquetamab to Simultaneously Target BCMA and GPRC5D in Patients With R/R Multiple Myeloma - 9 month(s) ago
At the 2023 ASCO Annual Meeting, Yael C Cohen, MD, presents results of the RedirecTT-1 study of the combination of teclistamab and talquetamab for the treatment of patients with R/R multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 ASCO Annual Meeting #ASCO2023, Yael Cohen, MD, presented results of the RedirecTT-1 trial on the combination of #teclistamab and #talquetamab targeting bispecifics #BCMA and #GPRC5D for patients with #MultipleMyeloma. https://t.co/3uEGrm90CW @ASCO https://t.co/05oaUOiWI6
-
-
Mashup Score: 0Teclistamab Triplet Elicits Clinical Activity in R/R Multiple Myeloma - 10 month(s) ago
In an interview, Emma Searle, MBChB, PhD, MA, MRCP, FRCPath, discussed results from cohort E of the MajesTEC-2 study of teclistamab in relapsed/refractory multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this interview, Emma Searle, MBChB, PhD, MA, MRCP, FRCPath, discussed results from cohort E of the MajesTEC-2 study, which evaluated #teclistamab in relapsed/refractory multiple myeloma. #mmsm https://t.co/wthPXp9xH6 https://t.co/pqTZhN6Ek7
-
-
Mashup Score: 0Teclistamab Long-term Response RR Multiple Myeloma - 10 month(s) ago
by: Niels Van de Donk, MD, Amsterdam UMC Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, continues to show promising results in patients with relapsed/refractory multiple myeloma (RRMM) based on long-term follow-up from the MajesTEC-1 study. After approximately 2 years of follow-up, p…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 Teclistamab video https://t.co/HlQ0n2SI0a on Long-term Response RR Multiple Myeloma #Teclistamab #MultipleMyeloma #MajesTEC1Study #BispecificAntibody - Niels Van de Donk, MD https://t.co/1cj1HOcpdt
-
-
Mashup Score: 2FDA Approves Teclistamab, a Promising New Drug for Multiple Myeloma Targeting BCMA and CD3 Proteins - 10 month(s) ago
Learn how FDA approval of a new multiple myeloma drug will brighten the outlook for people with resistant forms of the disease.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read more about Dr. Usmani's work with #Teclistamab here. https://t.co/8yic5a7syg
-
-
Mashup Score: 1Dosing and Toxicity: Considerations for Administering Teclistamab in R/R Multiple Myeloma - 11 month(s) ago
During a Targeted Oncology™ Case-Based Roundtable™ event, Shaji Kumar, MD, discussed with participants the key considerations of administering the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Shaji Kumar, MD, discussed key considerations of administering #teclistamab for patients with relapsed/refractory multiple myeloma. #mmsm | @MayoClinic @MayoCancerCare https://t.co/eSstGuXmlt
-
-
Mashup Score: 1Addressing Dosing Methods With Teclistamab in Multiple Myeloma - 12 month(s) ago
Emma Searle, PhD, discusses the dosing approach of the MajestTEC-2 trial (NCT04722146) and sequencing teclistamab (Tecvayli) in patients with multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Emma Searle, PhD, discusses the dosing approach of the MajestTEC-2 trial and sequencing #teclistamab in patients with #multiplemyeloma. #mmsm https://t.co/8C23ZuqjVn
-
-
Mashup Score: 0Teclistamab Combined With Subcutaneous Daratumumab and Lenalidomide in Patients With Multiple Myeloma - 1 year(s) ago
Emma Searle, MD, discusses treatment with teclistamab combined with subcutaneous daratumumab and lenalidomide for patients with multiple myeloma.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Emma Searle, MD discusses findings from the MajesTEC-2 trial, evaluating #teclistamab combined with subcutaneous #daratumumab and #lenalidomide in patients with #MultipleMyeloma. Learn more about @DrEmmaSearle's research here! https://t.co/yyltoyoFZo https://t.co/fWoNsnhGHt
-
-
Mashup Score: 0The Multiple Myeloma Daily - 1 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/jDZYqYSUMi Thanks to @TargetedOnc #mmsm #teclistamab
-
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses the efficacy and safety with teclistamab for patients with relapsed/refractory multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rafael Fonseca, MD, discusses the efficacy and safety with #teclistamab for patients with relapsed/refractory #multiplemyeloma. #mmsm | @MayoClinic @Rfonsi1 https://t.co/BXQbWLA7SI https://t.co/8ofYDH9g9J
-
At the 2023 @ASCO annual meeting, Niels van de Donk, MD, PhD, presented results from the 2-year follow-up of the MajesTEC-1 trial, which indicated that #teclistamab yielded durable responses for pre-treated patients with #MultipleMyeloma. Learn more here: https://t.co/gPOy8EEqjZ https://t.co/pqqqULXpFd